The military testosterone policy announced by Defense Secretary Pete Hegseth is now under judicial scrutiny. A federal judge has ordered the Trump administration to explain why the Pentagon promotes testosterone replacement therapy (TRT) for older cisgender soldiers while banning transgender troops from the same treatments.
What the New Testosterone Policy Entails
On March 2025, Pete Hegseth unveiled a plan requiring male service members aged 30 and older to undergo screening for testosterone levels. Those with low levels can volunteer for TRT to boost muscle mass, bone density, and overall “lethality.” Hegseth framed the policy as part of a broader effort to create a “High-T department of war,” using language that echoes former President Donald Trump’s rebranding of the Pentagon.
Get the #1 Wireless Door Camera
REOLINK Bestseller: 2K Weatherproof Video Doorbell, No Monthly Fees.
Key Provisions of the Policy
- Mandatory testosterone screening for all male service members aged 30+
- Voluntary enrollment in testosterone replacement therapy for those with low levels
- Goal: keep troops on the “leading edge of lethality”
- No equivalent program for female or transgender personnel
Judge Ana Reyes Questions the Discrepancy
On Wednesday, District Judge Ana Reyes issued an order demanding the Pentagon justify the apparent inconsistency. She pointed to Trump’s executive order banning transgender troops, which argued that hormone treatments disqualify individuals from military service. Yet the new policy actively encourages TRT for cisgender soldiers.
“The Armed Forces must adhere to high mental and physical health standards… without the benefit of routine medical treatment or special provisions,” Judge Reyes wrote, quoting the executive order. She requested detailed information on the cost, administration, and rationale behind treating transgender men differently from other service members under this TRT initiative.
Comparison of TRT Policies for Cisgender vs. Transgender Troops
| Aspect | Cisgender Soldiers (30+) | Transgender Soldiers |
|---|---|---|
| Access to testosterone therapy | Voluntary, encouraged | Banned under Trump EO |
| Medical justification | Optimize performance | Deemed disqualifying |
| Age requirement | 30+ male only | All ages, transgender |
| Official stance | “Keeping you on the leading edge of lethality” | “Routine treatment is incompatible” |
Key Takeaways
- The Pentagon’s testosterone screening targets a specific demographic while excluding others from similar care.
- A federal judge is scrutinizing the legal and medical rationale behind the conflicting policies.
- The outcome could affect thousands of active-duty service members and shape future military health standards.
- Legal experts expect the ruling to set a precedent for how hormone therapy is viewed in the armed forces.
FAQ
What is testosterone replacement therapy (TRT)?
TRT is a medical treatment that raises testosterone levels in men with low levels. It can improve energy, muscle mass, bone density, and libido. The military’s new policy makes TRT available to male soldiers aged 30 and older who screen low.
Why is a federal judge involved in this policy?
Judge Ana Reyes is overseeing one of two lawsuits challenging Trump’s ban on transgender troops. She noticed that the military is now actively promoting hormone therapy to cisgender soldiers, contradicting the rationale used to exclude transgender service members. She has ordered the Pentagon to explain the discrepancy.
What are the potential consequences of this legal challenge?
If the judge finds the policy inconsistent, it could be halted or revised. The case may also force the Pentagon to either expand TRT access to transgender troops or abandon the program altogether. The decision could influence future military medical policies and equal treatment protections.
As the Pentagon prepares its response, service members and advocacy groups are watching closely. The intersection of military readiness, hormone therapy, and gender equality has never been more sharply defined. Stay informed as this story develops.